{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T20:12:16Z","timestamp":1788120736805,"version":"build-2803163510"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[1998,7,1]],"date-time":"1998-07-01T00:00:00Z","timestamp":899251200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1998,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We have studied the potential stereoselective transport and metabolism of R\/S-verapamil in rat jejunum, in-situ.<\/jats:p><jats:p>A regional single-pass perfusion of the rat jejunum was performed on 24 rats in six separate groups. The effective permeability (Peff) was assessed for three different concentrations of verapamil, 4, 40 and 400 mg L\u22121. The Peff of each enantiomer was also determined at 400 mg L\u22121 when chlorpromazine (10 mM) was added to the perfusion solution. Two other groups of rats received R\/S-verapamil as an intravenous infusion and the intestinal secretion and metabolism were studied by simultaneously perfusing the jejunum with a control or with chlorpromazine (10 mM) added. The concentrations in the outlet perfusate of each enantiomer of verapamil and norverapamil were assayed with HPLC. R\/S-Verapamil is a high permeability drug in the proximal rat small intestine throughout the luminal concentration range studied and complete intestinal absorption was expected. There was an increase of Peff from 0.42 times 10\u22124 cm s\u22121 to 0.80 times 10\u22124 cm s\u22121 (P &amp;lt; 0.05) at concentrations from 4 to 400 mg L\u22121, respectively. The observed concentration-dependent jejunal Peff and fraction absorbed (P &amp;lt; 0.05) of R\/S-verapamil is consistent with the saturation of an efflux mechanism. When chlorpromazine (a P-glycoprotein inhibitor\/substrate) was added the jejunal Peff increased to 1.47 times 10\u22124 cm s\u22121. There was no difference between the Peff of the two enantiomers in any of these experiments. The efflux of R\/S-norverapamil into the rat jejunum was high after intravenous administration of R\/S-verapamil, suggesting extensive metabolism in the enterocyte.<\/jats:p><jats:p>In conclusion, both R\/S-verapamil enantiomers are P-glycoprotein substrates, but there is no stereoselective transport of R\/S-verapamil in the rat jejunum. The results also suggests that R\/S-norverapamil is formed inside the enterocytes.<\/jats:p>","DOI":"10.1111\/j.2042-7158.1998.tb07133.x","type":"journal-article","created":{"date-parts":[[2011,4,13]],"date-time":"2011-04-13T15:01:16Z","timestamp":1302706876000},"page":"729-735","source":"Crossref","is-referenced-by-count":45,"title":["The Absence of Stereoselective P-Glycoprotein-mediated Transport of<i>R\/S<\/i>-Verapamil Across the Rat Jejunum"],"prefix":"10.1093","volume":"50","author":[{"given":"Rikard","family":"Sandstr\u00f6m","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Division of Biopharmaceutics and Pharmacokinetics, University of Uppsala , S-751 23 Uppsala"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Karlsson","sequence":"additional","affiliation":[{"name":"Astra H\u00e4ssle AB , S-431 83 M\u00f6lndal,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Lennern\u00e4s","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Division of Biopharmaceutics and Pharmacokinetics, University of Uppsala , S-751 23 Uppsala"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[1998,7,1]]},"reference":[{"key":"2024103110041399500_cit1","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/0163-7258(93)90011-2","article-title":"Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals","volume":"60","author":"Borst","year":"1993","journal-title":"Pharmacol. Ther."},{"key":"2024103110041399500_cit2","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0090-9556(25)07406-9","article-title":"Stereo- and regioselective N- and S-oxidation of tertiary amines and sulfides in the presence of adult human liver microsomes","volume":"21","author":"Cashman","year":"1993","journal-title":"Drug Metab. Dispos."},{"key":"2024103110041399500_cit3","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0022-3565(25)12474-9","article-title":"Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferase in rat and human hepatic and extrahepatic tissues","volume":"253","author":"De Waziers","year":"1990","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2024103110041399500_cit4","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1023\/A:1016065715308","article-title":"Comparison between permeability coefficients in rat and human jejunum","volume":"13","author":"Fagerholm","year":"1996","journal-title":"Pharm. Res."},{"key":"2024103110041399500_cit5","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/hep.510240407","article-title":"Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin","volume":"24","author":"Fromm","year":"1996","journal-title":"Hepatology"},{"key":"2024103110041399500_cit6","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0009-9236(96)90182-4","article-title":"Direct demonstration of small intestinal secretion and site-dependent absorption of the beta-blocker talinolol in humans","volume":"59","author":"Gramatte","year":"1996","journal-title":"Clin. Pharmacol. Ther."},{"key":"2024103110041399500_cit7","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/0968-0004(92)90419-A","article-title":"Is the multidrug transporter a flippase","volume":"17","author":"Higgins","year":"1992","journal-title":"Trends Biochem. Sci."},{"key":"2024103110041399500_cit8","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/j.1476-5381.1993.tb13914.x","article-title":"Transport of celiprolol across human intestinal epithelial (Caco-2) cells: mediation of secretion by multiple transporters including P-glycoprotein","volume":"110","author":"Karlsson","year":"1993","journal-title":"Br. J. Pharmacol."},{"key":"2024103110041399500_cit9","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/S0022-3565(25)11408-0","article-title":"Predictability of the in vivo metabolism of verapamil from in vitro data: contribution of individual metabolic pathways and stereoselective aspects","volume":"260","author":"Kroemer","year":"1992","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2024103110041399500_cit10","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1023\/A:1018916017723","article-title":"Dose-dependent intestinal absorption and significant intestinal excretion (exsorption) of the beta-blocker pafenolol in the rat","volume":"10","author":"Lennern\u00e4s","year":"1993","journal-title":"Pharm. Res."},{"key":"2024103110041399500_cit11","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1023\/A:1018965328626","article-title":"Evidence for an interaction between the beta-blocker pafenolol and bile salts in the intestinal lumen of the rat leading to dose-dependent oral absorption and double peaks in the plasma concentration-time profile","volume":"10","author":"Lennern\u00e4s","year":"1993","journal-title":"Pharm. Res."},{"key":"2024103110041399500_cit12","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1023\/A:1015888813741","article-title":"Regional jejunal perfusion, a new in vivo approach to study oral drug absorption in man","volume":"9","author":"Lennern\u00e4s","year":"1992","journal-title":"Pharm. Res."},{"key":"2024103110041399500_cit13","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1172\/JCI113464","article-title":"Use of laminar flow and unstirred layer models to predict intestinal absorption in the rat","volume":"81","author":"Levitt","year":"1988","journal-title":"J. Clin. Invest."},{"key":"2024103110041399500_cit14","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0009-9236(97)90027-8","article-title":"Role of intestinal P-glycoprotein (*mdrl) in interpatient variation in the oral bio-availability of cyclosporine","volume":"62","author":"Lown","year":"1997","journal-title":"Clin. Pharmacol. Ther."},{"key":"2024103110041399500_cit15","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/clpt.1983.66","article-title":"Verapamil plasma binding: relationship to alpha 1-acid glycoprotein and drug efficacy","volume":"33","author":"McGowan","year":"1983","journal-title":"Clin. Pharmacol. Ther."},{"key":"2024103110041399500_cit16","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/S0090-9556(25)08410-7","article-title":"Reversal of stereoselectivity in the hepatic availability of verapamil in isolated perfused rat livers: role of protein binding","volume":"24","author":"Mehvar","year":"1996","journal-title":"Drug Metab. Dispos."},{"key":"2024103110041399500_cit17","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/0006-2952(90)90160-M","article-title":"The activity of verapamil as a resistance modifier in vitro in drug-resistant human tumour cell lines is not stereospecific","volume":"39","author":"Plumb","year":"1990","journal-title":"Biochem. Pharmacol."},{"key":"2024103110041399500_cit18","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/(SICI)1099-081X(199610)17:7<577::AID-BDD984>3.0.CO;2-P","article-title":"Enantioselective distribution of verapamil and norverapamil into human and rat erythrocytes: the role of plasma protein binding","volume":"17","author":"Robinson","year":"1996","journal-title":"Biopharm. Drug Dispos."},{"key":"2024103110041399500_cit19","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1023\/A:1016217505990","article-title":"Possible involvement of multiple P-glycoprotein-mediated efflux systems in the transport of verapamil and other organic cations across rat intestine","volume":"12","author":"Saitoh","year":"1995","journal-title":"Pharm. Res."},{"key":"2024103110041399500_cit20","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/0092-8674(94)90212-7","article-title":"Disruption of the mouse mdrla P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs","volume":"77","author":"Schinkel","year":"1994","journal-title":"Cell"},{"key":"2024103110041399500_cit21","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1073\/pnas.94.8.4028","article-title":"Normal viability and altered pharmacokinetics in mice lacking mdrl-type (drug-transporting) P-glycoproteins","volume":"94","author":"Schinkel","year":"1997","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2024103110041399500_cit22","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1073\/pnas.94.5.2031","article-title":"Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine","volume":"94","author":"Sparreboom","year":"1997","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2024103110041399500_cit23","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1152\/physrev.1997.77.2.545","article-title":"Kinetics of the multidrug transporter (P-glycoprotein) and its reversal","volume":"77","author":"Stein","year":"1997","journal-title":"Physiol. Rev."},{"key":"2024103110041399500_cit24","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/j.2042-7158.1996.tb05904.x","article-title":"Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier","volume":"48","author":"Terao","year":"1996","journal-title":"J. Pharm. Pharmacol."},{"key":"2024103110041399500_cit25","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0009-9236(96)90177-0","article-title":"Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism","volume":"59","author":"Thummel","year":"1996","journal-title":"Clin. Pharmacol. Ther."},{"key":"2024103110041399500_cit26","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/BF00500311","article-title":"Secretion of monoquaternary ammonium compounds by guinea-pig small intestine in vivo","volume":"299","author":"Turnheim","year":"1977","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"2024103110041399500_cit27","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S0022-3565(25)31976-2","article-title":"Interaction between intestinal absorption and secretion of monoquaternary ammonium compounds in guinea-pigs\u2014a concept for the absorption kinetics of organic cations","volume":"212","author":"Turnheim","year":"1980","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"2024103110041399500_cit28","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1016\/0006-2952(83)90019-9","article-title":"Binding of phenothiazine neuroleptics to plasma proteins","volume":"32","author":"Verbeeck","year":"1983","journal-title":"Biochem. Pharmacol."},{"key":"2024103110041399500_cit29","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/mc.2940130302","article-title":"Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy","volume":"13","author":"Wacher","year":"1995","journal-title":"Mol. Carcinog."},{"key":"2024103110041399500_cit30","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1023\/A:1016029601311","article-title":"Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: concentration- and dose-dependent absorption in vitro and in vivo","volume":"13","author":"Wetterich","year":"1996","journal-title":"Pharm. Res."},{"issue":"Suppl. 2","key":"2024103110041399500_cit31","first-page":"50.","article-title":"Correlation of drug permeability in humans (in vivo) with experimentally and theoretically derived parameters","volume":"5","author":"Winiwarter","year":"1997","journal-title":"Eur. J. Pharm. Sci."}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.2042-7158.1998.tb07133.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/50\/7\/729\/60262460\/j.2042-7158.1998.tb07133.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/50\/7\/729\/60262460\/j.2042-7158.1998.tb07133.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T01:46:48Z","timestamp":1741139208000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/50\/7\/729\/6153008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,7,1]]},"references-count":31,"journal-issue":{"issue":"7","published-online":{"date-parts":[[1998,7,1]]},"published-print":{"date-parts":[[1998,7,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.2042-7158.1998.tb07133.x","relation":{},"ISSN":["2042-7158","0022-3573"],"issn-type":[{"value":"2042-7158","type":"electronic"},{"value":"0022-3573","type":"print"}],"subject":[],"published-other":{"date-parts":[[1998,7]]},"published":{"date-parts":[[1998,7,1]]}}}